{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:00:15Z","timestamp":1791388815801,"version":"4.3.3"},"reference-count":9,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.endinu.2017.01.005","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T03:15:40Z","timestamp":1489547740000},"page":"272-273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Diabetes fulminante secundaria a tratamiento con pembrolizumab"],"prefix":"10.1016","volume":"64","author":[{"given":"Chadia","family":"Mizab Mellah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"S\u00e1nchez P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Santos Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Hern\u00e1ndez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.endinu.2017.01.005_bib0050","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJM200002033420501","article-title":"A novel subtype of diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies","volume":"342","author":"Imagawa","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endinu.2017.01.005_bib0055","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2337\/diacare.26.8.2345","article-title":"Fulminant type 1 diabetes: A nationwide survey in Japan","volume":"26","author":"Imagawa","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endinu.2017.01.005_bib0060","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jdi.12024","article-title":"Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012)","volume":"3","author":"Imagawa","year":"2012","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.endinu.2017.01.005_bib0065","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s00125-004-1626-x","article-title":"Different contribution of class II HLA in fulminant and typical autoinmune type 1 diabetes mellitus","volume":"48","author":"Imagawa","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.endinu.2017.01.005_bib0070","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/cei.12603","article-title":"Low programmed cell death-1 (PD-1) expression in peripheral CD41 T cells in Japanese patients with autoimmune type 1 diabetes","volume":"180","author":"Fujisawa","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.endinu.2017.01.005_bib0075","doi-asserted-by":"crossref","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports","volume":"11","author":"Noha","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.endinu.2017.01.005_bib0080","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endinu.2017.01.005_bib0085","doi-asserted-by":"crossref","unstructured":"Chae YK, Chiec L, Mohindra N, Gentzler R, Patel J, Giles F. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. Cancer Immunol Immunother. 2017; 66: 25-32. DOI: 10.2337\/dc14-2349","DOI":"10.1007\/s00262-016-1913-7"},{"key":"10.1016\/j.endinu.2017.01.005_bib0090","doi-asserted-by":"crossref","unstructured":"Munakata W, Ohashi K, Yamauchi N, Tobinai K. Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. Int J Hematol. En prensa 2016. DOI: 10.1007\/s12185-016-2101-4. Epub 2016 Oct 1.","DOI":"10.1007\/s12185-016-2101-4"}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530016417300472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530016417300472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T05:34:25Z","timestamp":1658813665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530016417300472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S2530016417300472"],"URL":"https:\/\/doi.org\/10.1016\/j.endinu.2017.01.005","relation":{},"ISSN":["2530-0164"],"issn-type":[{"value":"2530-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetes fulminante secundaria a tratamiento con pembrolizumab","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endinu.2017.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 SEEN. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}